Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | SVP, Clinical Operations | September 15, 2026 | September 17, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | SVP, Clinical Operations | October 03, 2022 | October 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.34 · Expires 2036-09-15 | IndirectBy Son | 1,000 |
Reported balance
After 2026-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 1,000 · Balance 1,000 F1: The shares underlying this option vest in four equal installments on September 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service with the Issuer at each vesting date. F2: Represents a stock option granted to the Reporting Person's son in connection with the commencement of his employment with the Issuer. The Reporting Person disclaims beneficial ownership of all securities held by her son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in four equal installments on September 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service with the Issuer at each vesting date.
F2: Represents a stock option granted to the Reporting Person's son in connection with the commencement of his employment with the Issuer. The Reporting Person disclaims beneficial ownership of all securities held by her son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 11,653 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 13,000 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 3,750 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 775 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-03 · Disposition to issuer · Disposed 25,225 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-03 · Disposition to issuer · Disposed 2,398 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-03 · Disposition to issuer · Disposed 27,602 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.99 · Expires 2029-11-25 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-03 · Disposition to issuer · Disposed 28,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.60 · Expires 2029-03-22 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-10-03 · Disposition to issuer · Disposed 6,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-10-03 · Disposition to issuer · Disposed 61,916 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-10-03 · Disposition to issuer · Disposed 3,084 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.28 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-10-03 · Disposition to issuer · Disposed 590 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.28 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-10-03 · Disposition to issuer · Disposed 41,432 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.62 · Expires 2027-09-04 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-10-03 · Disposition to issuer · Disposed 9,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2027-04-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-10-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 1,199 | Not disclosed Strike: $4.13 | Not disclosed |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 20 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199 Underlying: Common Shares · 1,199 shares Expires 2031-01-06 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 12,612 | Not disclosed Strike: $6.37 | Not disclosed |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 19 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,612 Underlying: Common Shares · 12,612 shares Expires 2032-01-07 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 387 | Not disclosed Strike: $6.37 | Not disclosed |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · derivative · entry 18 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387 Underlying: Common Shares · 387 shares Expires 2032-01-07 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 37,492 | $7.00 | $262,444.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 17 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,969 F3 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 12,500 | $0.54 | $6,750.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 16 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 4,500 | $1.86 | $8,370.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 15 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 20,716 | $1.03 | $21,337.48 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 14 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 295 | $1.03 | $303.85 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 13 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 1,542 | $1.61 | $2,482.62 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 12 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 30,958 | $1.61 | $49,842.38 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 11 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 3,000 | $2.52 | $7,560.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 10 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 14,000 | $2.84 | $39,760.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 9 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 13,801 | $4.13 | $56,998.13 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 8 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 1,199 | $4.13 | $4,951.87 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 7 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 12,612 | $6.37 | $80,338.44 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 6 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 387 | $6.37 | $2,465.19 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 5 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 4 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,951 F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,076 F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,326 F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:42 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 5,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007085 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,826 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 21:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantRestricted Share Unit Award · Derivative | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000354 · primarydocument.xml · derivative · entry 5 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F6 · derivative.exercise_date: The reporting person was granted 13,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date. 100% of these restricted share units are generally subject to settlement upon separation from service. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 21:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $128.87 | $0.00 |
DisclosureSEC source: 0001562180-22-000354 · primarydocument.xml · derivative · entry 4 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Shares · 26,000 shares Expires 2032-01-07 F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionRestricted Share Unit Award · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000354 · primarydocument.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F2 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Tax withholdingCommon Shares | 1,800 | $123.86 | $222,948.00 |
DisclosureSEC source: 0001562180-22-000354 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,653 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000354 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2021 Filed Nov 26, 2021 16:30 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionRestricted Share Unit Award · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-007301 · primarydocument.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the issuer. F2 · price: Each restricted share unit represents the contingent right to receive one common share of the issuer. F3 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| November 25, 2021 Filed Nov 26, 2021 16:30 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Tax withholdingCommon Shares | 1,738 | $115.55 | $200,825.90 |
DisclosureSEC source: 0001562180-21-007301 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,703 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| November 25, 2021 Filed Nov 26, 2021 16:30 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-007301 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 20:48 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionRestricted Share Unit Award · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000273 · primarydocument.xml · derivative · entry 5 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 20:48 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantRestricted Share Unit Award · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000273 · primarydocument.xml · derivative · entry 4 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 20:48 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $83.38 | $0.00 |
DisclosureSEC source: 0001562180-21-000273 · primarydocument.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2031-01-06 F2 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 20:48 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Tax withholdingCommon Shares | 1,747 | $83.38 | $145,664.86 |
DisclosureSEC source: 0001562180-21-000273 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,691 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 20:48 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000273 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2020 Filed Nov 27, 2020 21:48 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionRestricted Share Unit Award · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006939 · primarydocument.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F2 · price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| November 25, 2020 Filed Nov 27, 2020 21:48 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Tax withholdingCommon Shares | 1,701 | $90.14 | $153,328.14 |
DisclosureSEC source: 0001562180-20-006939 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,688 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| November 25, 2020 Filed Nov 27, 2020 21:48 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006939 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 18:42 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleEmployee Stock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001562180-20-006335 · primarydocument.xml · derivative · entry 5 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,500 shares Expires 2026-12-14 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: The shares underlying this option vested in four equal installments on December 15, 2016, December 15, 2017, December 15, 2018 and December 15, 2019. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 18:42 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 2,458 | $77.42 | $190,300.08 |
DisclosureSEC source: 0001562180-20-006335 · primarydocument.xml · nonDerivative · entry 4 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,639 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.075 - $77.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 18:42 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 15,781 | $76.42 | $1,205,938.26 |
DisclosureSEC source: 0001562180-20-006335 · primarydocument.xml · nonDerivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,097 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 - $76.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 18:42 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 5,261 | $75.62 | $397,843.66 |
DisclosureSEC source: 0001562180-20-006335 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,878 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.02 - $76.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 18:42 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 23,500 | $9.29 | $218,315.00 |
DisclosureSEC source: 0001562180-20-006335 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 21:55 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001562180-20-004575 · primarydocument.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Common Shares · 24,000 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The shares underlying this option vested in four equal installments on October 23, 2015, October 23, 2016, October 23, 2017 and October 23, 2018. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 21:55 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 24,000 | $70.20 | $1,684,869.60 |
DisclosureSEC source: 0001562180-20-004575 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,639 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 - $70.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 21:55 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 24,000 | $5.60 | $134,400.00 |
DisclosureSEC source: 0001562180-20-004575 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:51 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleEmployee Stock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001562180-20-004603 · primarydocument.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 400 shares Expires 2025-10-22 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The shares underlying this option vested in four equal installments on October 23, 2015, October 23, 2016, October 23, 2017 and October 23, 2018. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:51 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 400 | $70.20 | $28,081.16 |
DisclosureSEC source: 0001562180-20-004603 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,639 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 - $70.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:51 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 400 | $5.60 | $2,240.00 |
DisclosureSEC source: 0001562180-20-004603 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:24 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 600 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001562180-20-004419 · primarydocument.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Shares · 600 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The shares underlying this option vested in four equal installments on October 23, 2015, October 23, 2016, October 23, 2017 and October 23, 2018. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:24 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 600 | $70.05 | $42,027.48 |
DisclosureSEC source: 0001562180-20-004419 · primarydocument.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,639 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.04 - $70.075, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:24 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 600 | $5.60 | $3,360.00 |
DisclosureSEC source: 0001562180-20-004419 · primarydocument.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.